The FDA has granted accelerated approval to Novartis’ Vanrafia for adults with primary immunoglobulin A nephropathy (IgAN).

Astellas Pharma has entered a strategic partnership with the JFCR to expedite research in translational and clinical oncology ...

But while platform trials have the potential to be more effective and less expensive than traditional trials, challenges ...

The push for reducing funding and the workforce at the FDA comes partly from US Secretary of Health and Human Services Robert ...

At the BioTrinity Conference, experts champion government funding programmes to bridge gap the in UK venture capital ...

Panellists at the OBN BioTrinity 2025 conference in London discussed how US uncertainty is impacting the biopharma environment.

T2D has been associated with an increased risk of CV mortality and GLP-1RAs are being increasingly used as a T2D and obesity ...

Organon has announced the acquisition from Biogen of US regulatory and commercial rights for intravenous infusion of ...

Plans outlined by HHS Secretary Robert F Kennedy, Jr look set to target jobs at the US Department of Health & Human Services (HHS).

The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

Amneal Pharmaceuticals and Shilpa Medicare have launched the new presentation of bortezomib, Boruzu, for subcutaneous or ...

Apellis Pharmaceuticals has announced US FDA acceptance of the sNDA and the granting of priority review status to Empaveli ...